Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $10.76 Analyst target: $26.88 Upside: 149.81%
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.